BET proteins cooperate with oncogenic drivers that are cancer type specific, including androgen receptor signaling in prostate cancer (45), GLI1 in glioblastoma (46), and MYC activity in hematologic malignancies (47). This evidence concerns the gene DNER and prostate cancer.